Stock Details
GRFS is Grifols, S.A.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 12.09$. Average daily volumn in 3 months 872.18k. Market cap 11.39B



Stock symbol : GRFS. Exchange : NasdaqGS. Currency : USD
Lastest price : 12.33$. Total volume : 604.41k. Market state REGULAR
Click reload if you want to check the lastest price on market!!!

Grifols, S.A. (GRFS)
Last Price
12.33$
Change
0.45
Volume
604.41k

Previous Close11.88
Open11.74
Day Range11.74-12.37
Bid12.37 x 800
Ask12.38 x 900
Volume604.41k
Average Volume872.18k
Market Cap11.39B
Beta0.17
52 Week Range10.10-17.45
Trailing P/E42.52
Foward P/E14.34
Dividend (Yield %)N/A
Ex-Dividend Date2021-06-03



Financial Details


According to Grifols, S.A.'s financial reports the company's revenue in 2021 were 4.93B an decrease(-20%) over the years 2020 revenue that were of 5.34B. In 2021 the company's total earnings were 182.8M while total earnings in 2020 were 618.55M(-70.55%).


Loading ...



Organization

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting fa... ctors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Market Cap:
11.39B
Revenue:
4.93B
Total Assets:
19.23B
Total Cash:
655.49M


News about "Grifols, S.A."

grifols-nasdaqgrfs-stock-price-down-82-on-analyst-downgrade-image

Grifols (NASDAQ:GRFS) Stock Price Down 8.2% on Analyst Downgrade

Source from : Defense World - 1 days ago

Grifols, S.A. (NASDAQ:GRFS – Get Rating) was down 8.2% on Wednesday after Berenberg Bank lowered their price target on the stock from €21.40 to €20.60. Berenberg Bank currently has a buy rating on the ...See details»


Grifols S.A. (GRFS) is on the roll with an average volume of 955.04K in the recent 3 months

Source from : investchronicle - 1 days ago

Grifols S.A. (GRFS) is priced at $11.30 after the most recent trading session. At the very opening of the session, the stock price was $11.41 and reached a high price of $11.45, prior to closing the ...See details»


grifols-sa-nasdaqgrfs-receives-consensus-recommendation-of-hold-from-brokerages-image

Grifols, S.A. (NASDAQ:GRFS) Receives Consensus Recommendation of “Hold” from Brokerages

Source from : Defense World - 8 days ago

Shares of Grifols, S.A. (NASDAQ:GRFS – Get Rating) have earned an average recommendation of “Hold” from the eight ratings firms that are presently covering the company, Marketbeat reports. One ...See details»


grifols-tells-investors-is-not-currently-studying-capital-hike-source-image

Grifols tells investors is not currently studying capital hike - source

Source from : Reuters - 1 days ago

Spanish pharmaceuticals company Grifols is not analysing any increase in share capital for the timebeing, Grifols' vice president told investors on Thursday, according to a market source.See details»


Grifols, S.A. (NASDAQ:GRFS) Receives Average Rating of “Hold” from Brokerages

Source from : ETF Daily News - 8 days ago

Shares of Grifols, S.A. (NASDAQ:GRFS – Get Rating) have been assigned a consensus rating of “Hold” from the eight research firms that are covering the stock, MarketBeat.com reports.See details»


Pharma giant gets rolling on 300-job Clayton expansion that could get even bigger

Source from : The Business Journals - 3 days ago

Back in June 2020, Grifols S.A. (Nasdaq: GRFS) announced it was expanding in Clayton by adding 300 jobs through a $350 million investment. Earlier this month, the Clayton Town Council approved a ...See details»


Grifols SA Pref (GRLSbn)

Source from : Investing.com - 4 days ago

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...See details»


interesting-grfs-put-and-call-options-for-february-2023-image

Interesting GRFS Put And Call Options For February 2023

Source from : Nasdaq - 10 days ago

I nvestors in Grifols SA, Barcelona (Symbol: GRFS) saw new options become available this week, for the February 2023 expiration. One of the key inputs that goes into the price an ...See details»


GRFS Crosses Above Key Moving Average Level

Source from : Nasdaq - 4 days ago

In trading on Monday, shares of Grifols SA, Barcelona (Symbol: GRFS) crossed above their 200 day moving average of $12.14, changing hands as high as $12.30 per share. Grifols SA, Barcelona shares are ...See details»


grifols-rebota-un-95-en-dos-días-tras-descartar-una-ampliación-de-capital-de-2000-millones-de-euros-image

Grifols rebota un 9,5% en dos días tras descartar una ampliación de capital de 2.000 millones de euros

Source from : Europa Press on MSN.com - 8 hours ago

Grifols acumula una revalorización en Bolsa del 9,5% en los dos últimos días, después de descartar que no está analizando ninguna operación para ampliar su capital en 2.000 millones de euros, una oper ...See details»


grifols-rebota-un-95-tras-descartar-una-ampliación-de-capital-y-el-ibex-sube-un-1-image

Grifols rebota un 9,5% tras descartar una ampliación de capital y el ibex sube un 1%

Source from : The Objective - 7 hours ago

El Ibex 35 se ha anotado un avance del 0,96% en la sesión, hasta situarse en los 8.176,1 puntos, aunque ha presentado un retroceso del 0,82% en una semana ...See details»


Grifols: Aspectos a destacar del Investor´s Day.

Source from : Capitalbolsa - 16 hours ago

El Investor´s Day de Grifols nos ha servido principalmente para confirmar que, la recuperación del negocio subyacente prosigue su marcha ascendente, incluso acelerándose en las últimas semanas en para ...See details»


Grifols S.A. (GRLS)

Source from : Investing - 3 days ago

Aviso legal: Las operaciones con instrumentos financieros o criptomonedas implican un elevado riesgo, incluyendo la pérdida parcial o total del capital invertido, y pueden no ser adecuadas para ...See details»


Plasma Fractionation Market Share Growing Rapidly with Leading Players 2028 | Grifols, S.A., Octapharma AG, Kedrion S.P.A., Shire plc

Source from : Digital Journal - 4 days ago

The global plasma fractionation market size was significantly robust in 2020 and is expected to register a steady revenue CAGR over the forecast period. Key factors providing impetus to market ...See details»